Business Wire - December 1, 2006

This report analyzes the worldwide markets for Antivirals in US$ Million. The major product segments analyzed are HIV Antivirals (Reverse Transcriptase Inhibitors (RTIs) (Nucleotide Reverse Transcriptase Inhibitors (NRTIs), and Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTIs)), and Protease Inhibitors (PIs), Hepatitis B & C Antivirals (Hepatitis C Antivirals, and Hepatitis B Antivirals), Herpes Simplex Virus (HSV) Antivirals, Influenza Antivirals, Respiratory Syncytial Virus (RSV) Antivirals, and Human Papilloma Virus (HPV) Antivirals. The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual forecasts are provided for the period of 2000 through 2010. The report profiles 139 companies including many key and niche players worldwide. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

The Companies mentioned inside this report include:

-- M Company (USA)

-- M Pharmaceuticals (USA)

-- Abbott Laboratories (USA)

-- Achillion Pharmaceuticals, Inc (USA)

-- Adithya Pharmaceuticals Pvt, Ltd (India)

-- Adventrx Pharmaceuticals, Inc (USA)

-- Aeterna Zentaris, Inc (Canada)

-- Aethlon Medical, Inc (USA)

-- Alfacell Corporation (USA)

-- Alnylam Pharmaceuticals, Inc (USA)

-- Amarillo Biosciences (USA)

-- Amazon Biotech (USA)

-- Amgen, Inc (USA)

-- Anadys Pharmaceuticals (USA)

-- Antigenics, Inc (USA)

-- Ares Serono (France)

-- Array BioPharma, Inc (USA)

-- Arrow Pharmaceuticals (Australia)

-- Aspen Pharmacare Holding Ltd (South Africa)

-- Astral Pharmaceuticals (India)

-- Astellas Pharma, Inc (Japan)

-- AstraZeneca PLC (UK)

-- Aurobindo Pharma Ltd (India)

-- Avanir Pharmaceuticals (USA)

-- Bavarian Nordic A/S (Denmark)

-- Bayer HealthCare AG (Germany)

-- Becton Dickinson and Company (USA)

-- Benitec Ltd (Australia)

-- Biomerieux SA (France)

-- Biomira, Inc (Canada)

-- Biota Holdings Limited (Australia)

-- Biovail Pharmaceuticals (Canada)

-- Boehringer Ingelheim GmbH (Germany)

-- Roxane Laboratories, Inc (USA)

-- Bristol-Myers Squibb Company (USA)

-- Bukwang Pharmaceutical Company Limited (South Korea)

-- Cavidi Tech AB (Sweden)

-- Celldex Therapeutics, Inc (USA)

-- CEL-SCI Corporation (USA)

-- ChemBridge Research Laboratories, Inc (USA)

-- Chimerix, Inc (USA)

-- Chongqing Jiachen Product Manufacturing Co, Ltd (China)

-- Coley Pharmaceutical Group, Inc (USA)

-- Cornerstone BioPharma, Inc (USA)

-- Cubist Pharmaceuticals, Inc (USA)

-- Cytogenix, Inc (USA)

-- Daiichi Pharmaceutical Co, Ltd (Japan)

-- Dainippon Sumitomo Pharma Company Ltd (Japan)

-- Digene Corporation (USA)

-- E I Du Pont De Nemours and Company (USA)

-- Eli Lilly and Company (USA)

-- Lilly Research Labs (USA)

-- Enanta Pharmaceuticals, Inc (USA)

-- Endo Labs (USA)

-- Enzo Diagnostics, Inc (USA)

-- F Hoffmann-La Roche Ltd (Switzerland)

-- Roche Laboratories, Inc (USA)

-- FermaVir Pharmaceuticals, Inc (USA)

-- Flamel Technologies SA (France)

-- Forest Laboratories, Inc (USA)

-- Galapagos NV (Belgium)

-- Genentech, Inc (USA)

-- Gen-Probe, Inc (USA)

-- Gilead Sciences, Inc (USA)

-- Girindus AG (Germany)

-- GlaxoSmithKline PLC (UK)

-- Health Enhancement Products, Inc (USA)

-- Hemispherx Biopharma, Inc (USA)

-- Hetero Drugs Ltd (India)

-- Human Genome Sciences, Inc (USA)

-- Idenix Pharmaceuticals, Inc (USA)

-- Idera Pharmaceuticals, Inc (USA)

-- Indian Immunologicals Ltd (India)

-- Innogenetics NV (Belgium)

-- Inovio Biomedical Corporation (USA)

-- Intarcia Therapeutics Inc (USA)

-- Intercell AG (Austria)

-- InterMune, Inc (USA)

-- Isis Pharmaceuticals, Inc (USA)

-- Japan Tobacco, Inc (Japan)

-- Johnson & Johnson (USA)

-- Janssen LP (USA)

-- Ortho-Clinical Diagnostics (USA)

-- Ortho Biotech Products

-- Tibotec Therapeutics Division (USA)

-- Tibotec Pharmaceuticals Ltd (Ireland)

-- Koronis Pharmaceuticals, Inc (USA)

-- Lupin Limited (India)

-- Medigene AG (Germany)

-- Medimmune, Inc (USA)

-- Medivir AB (Sweden)

-- Merck & Company, Inc (USA)

-- Merck Research Laboratories (USA)

-- MGI Pharma, Inc (USA)

-- Migenix, Inc (Canada)

-- Monogram Biosciences, Inc (USA)

-- Novactyl, Inc (USA)

-- Novartis AG (Switzerland)

-- Chiron Corporation (USA)

-- Novartis Pharmaceuticals Corporation (USA)

-- Sandoz International GmbH (Germany)

-- Novelos Therapeutics (USA)

-- Novosom AG (Germany)

-- Nucleonics, Inc (USA)

-- Oncogene Science, Inc (USA)

-- OraSure Technologies, Inc (USA)

-- Oxford BioMedica PLC (UK)

-- Panacos Pharmaceuticals, Inc (USA)

-- Pasteur Merieux Connaught (France)

-- PDL BioPharma, Inc (USA)

-- Peregrine Pharmaceuticals, Inc (USA)

-- Pfizer, Inc (USA)

-- Pharmasset, Inc (USA)

-- Pharmexa A/S (Denmark)

-- Procter & Gamble Pharmaceuticals (USA)

-- Receptopharm, Inc (USA)

-- REPLICor, Inc (Canada)

-- Rhein Biotech NV (The Netherlands)

-- Sanofi-Aventis (France)

-- Sareum Ltd (UK)

-- Schering AG (Germany)

-- Schering-Plough Corporation (USA)

-- SciClone Pharmaceuticals, Inc (USA)

-- Scigen Ltd (Australia)

-- Serum Institute of India Ltd (India)

-- SGX Pharmaceuticals, Inc (USA)

-- Shantha Biotechnics Pvt, Ltd (India)

-- Shionogi & Co, Ltd (Japan)

-- Sunesis Pharmaceuticals, Inc (USA)

-- Takeda Pharmaceutical Company Limited (Japan)

-- Targeted Genetics Corporation (USA)

-- TEVA Pharmaceutical Industries Ltd (Israel)

-- Ivax Corporation (USA)

-- The Immune Response Corporation (USA)

-- Three Rivers Pharmaceuticals (USA)

-- Titan Pharmaceuticals, Inc (USA)

-- Trimeris, Inc (USA)

-- Trinity Biotech PLC (Ireland)

-- Tripep AB (Sweden)

-- Valeant Pharmaceuticals International (USA)

-- VaxGen, Inc (USA)

-- Vertex Pharmaceuticals, Inc (USA)

-- Vical, Inc (USA)

-- Vion Pharmaceuticals (USA)

-- Viragen, Inc (USA)

-- Virco Laboratories, Inc (USA)

-- ViroPharma, Inc (USA)

-- Viscount Pharma, Inc (Canada)

-- Vybion, Inc (USA)

-- Wyeth (USA)

-- Xenomics, Inc (USA)

-- XTL Biopharmaceuticals Ltd (USA)

-- ZymeTx, Inc (USA)

-- ZymoGenetics, Inc (USA)

For more information visit: http://www.researchandmarkets.com/reports/c46367

CONTACT: Research and Markets

Laura Wood

Fax: +353 1 4100 980

press@researchandmarkets.com

SOURCE: Research and Markets Ltd.

061201
BW061201

Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .